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Abstract
Background: Respiratory symptoms are associated with accelerated lung function decline, and increased
hospitalization and mortality rates in the general population. Although several environmental risk factors for
respiratory symptoms are known, knowledge on genetic risk factors is lacking. We aim to identify genetic variants
associated with respiratory symptoms by genome-wide association (GWA) analyses.
Methods: We conducted the first GWA study on cough, dyspnea and phlegm among 7,976 participants in the
LifeLines I cohort and used the LifeLines II cohort (n = 5,260) and the Vlagtwedde-Vlaardingen cohort (n = 1,529)
for replication.
Results: We identified 50 SNPs that were assessed for replication. Rs16918212, located in the alpha-2-macroglobulin
pseudogene 1 (A2MP1), was associated with cough in both the identification (odds ratio (OR) = 0.72, p = 5.41 × 10−5)
and the meta-analyzed replication cohorts (OR = 0.83, p = 0.033). No other significant replicated associations were
found.
Conclusions: Given that only 1 out of 50 SNPs showed significant replication (i.e. 2%) we conclude that we did not
find a convincing association between genetic markers and respiratory symptoms. Since, environmental exposures
are important risk factors for respiratory symptoms, the next step is to perform a genome-wide interaction (GWI)
study to identify genetic susceptibility loci for respiratory symptoms in interaction with known harmful environmental
exposures.
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Background
The presence of respiratory symptoms, such as chronic
cough, dyspnea and phlegm, is associated with lower
lung function [1, 2] and with mortality due to several
causes of death [3–5]. Respiratory symptoms have been
regarded as important markers of accelerated lung func-
tion decline [6, 7] and development of asthma [8].
It is known that cigarette smoking [9], allergy [10, 11],
air pollution [12, 13] and occupational exposures [14, 15]
are risk factors for respiratory symptoms. However, not all
exposed subjects develop respiratory symptoms, which
suggests that a genetic component may be involved in the
development of respiratory symptoms. Previous studies
reported associations between respiratory symptoms and
specific genetic loci using candidate gene studies [16, 17].
To date, only one genome-wide association (GWA) study
has investigated genetic susceptibility of respiratory symp-
toms (i.e. Chronic mucus hyper-secretion) [18]. Genetic
susceptibility to develop respiratory symptoms such as
cough, dyspnea, and phlegm has not been studied up until
now using GWA methods.
In the current study, we conducted several GWA
analyses, i.e. on cough, dyspnea and phlegm, in 7,976
Caucasians of Dutch descent from the large population-
based LifeLines I cohort study to identify common genetic
variants associated with respiratory symptoms. We used
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the LifeLines II cohort and the Vlagtwedde-Vlaardingen
cohort to replicate our initial findings.
Methods
Identification cohort
Genotyped individuals from the first data release of the
LifeLines cohort study (2006–2011, LifeLines I) with full
data on all covariates were included (n = 7,976). The
LifeLines cohort study is a prospective population-based
cohort studying health and health-related behavior of
subjects from the three Northern provinces of the
Netherlands [19, 20].
Replication cohorts
We included 5,260 subjects from the second data release
from the LifeLines cohort study (2006–2011, LifeLines
II) and 1,529 subjects from the last survey (1989/1990)
from the Vlagtwedde-Vlaardingen cohort [21, 22], a pro-
spective general population based cohort including Cau-
casians of Dutch descent, to replicate our initial findings.
Ethics, consent and permissions
Participants provided written informed consent. The
study was approved by the Medical Ethics Committee of
the University Medical Center Groningen, Groningen,
The Netherlands (ref. METc 2007/152).
Genotyping and quality control
Genome-wide genotyping was performed in the identifica-
tion and replication cohorts using IlluminaCytoSNP-12
arrays. The IlluminaCytoSNP-12 is an oligonucleotide
chip designed to have a uniform spacing of markers across
all chromosomes, with the majority of the markers on this
chip reflecting common SNPs: 93% of the 301,232
markers on this chip reflect bi-allelic SNP markers. The
applied genotyping quality control criteria in the LifeLines
cohort and the Vlagtwedde-Vlaardingen cohort have been
described before [19, 20]: Samples with call-rates of less
than 95% were excluded as were samples of non-
Caucasians and first degree relatives. SNPs were excluded
if they had a genotype call-rate < 95%, minor allele fre-
quency (MAF) < 1%, or a Hardy-Weinberg equilibrium
(HWE) p-value < 10−4. In the LifeLines cohort 227,981
SNPs were included and in the Vlagtwedde-Vlaardingen
cohort 242,926 SNPs were included.
Respiratory symptoms
Cough, dyspnea, and phlegm were defined by standard-
ized questionnaires from the European Community Re-
spiratory Health Survey (ECRHS) [23]. Cough was defined
as at least one positive answer to the questions: “do you
usually cough first thing in the morning in the winter?” or
“do you usually cough during the day, or at night, in win-
ter?”. Dyspnea was defined as a positive answer to the
question: “are you troubled by shortness of breath when
hurrying on level ground or walking up a slight hill or
stairs at normal pace?”. Phlegm was defined as at least one
positive answer to the questions: “do you usually bring up
any phlegm from your chest first thing in the morning in
winter?” or “do you usually bring up any phlegm from
your chest during the day, or at night, in winter?”.
Statistical analysis
The data are presented as median (min-max) for con-
tinuous variables and as frequencies (percentages) for
categorical variables. The GWA analyses on the presence
of the respiratory symptoms cough, dyspnea, and
phlegm were performed using PLINK version 1.07 [24].
We used an additive genetic model adjusted for age, sex,
and current smoking. SNPs with a p-value < 10−4 in the
identification analysis were taken forward for replication.
Replication analysis was performed by analyzing the two
replication cohorts separately using logistic regression
model in PLINK version 1.07 [24] and subsequently
meta-analyzing effect estimates from both cohorts.
Significant replication was defined as a fixed effect meta-
analysis p-value < 0.05 and an effect estimate in the same
direction as in the identification GWA study. SNP anno-
tation was performed using HaploReg version 4 (Broad
Institute).
Results
Demographic characteristics and the prevalence of re-
spiratory symptoms in the study cohorts are summarized
in Table 1. In the identification cohort LifeLines I, the
median age of subjects was 47 years old, 43% were male,
and 24% were current smokers. The replication cohorts
were comparable with the identification cohort with
Table 1 Characteristics of the subjects included in the







N 7,976 5,260 1,521
Male, n (%) 3,420 (43) 2,112 (40) 805 (53)
Age (yrs), median (min-max) 47 (18–88) 48 (20–89) 53 (35–91)
Current smokers, n (%) 1,904 (24) 1,051 (20) 548 (36)
Smoking status, n (%)
Ever 4,737 (60) 3,050 (59) 1,054 (69)
Never 3,208 (40) 2,133 (41) 467 (31)
Respiratory symptoms, n (%)
Cough 1275 (16) 776 (15) 175 (12)
Dyspnea 1097 (17) 749 (17) 338 (22)
Phlegm 872 (11) 534 (11) 147 (10)
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respect to demographic characteristics. The prevalence
of respiratory symptoms in the LifeLines cohorts and
Vlagtwedde-Vlaardingen cohort varied from 10 to 22%.
The Manhattan plots of the GWAS of cough, dyspnea
and phlegm are shown in Additional file 1: Figures S1,
S2 and S3 respectively. A total of 17 SNPs, 19 SNPs
and 14 SNPs were identified for cough (Table 2), dyspnea
(Table 3) and phlegm (Table 4) in the identification ana-
lyses in LifeLines I, respectively, and taken forward for
replication in LifeLines II and Vlagtwedde-Vlaardingen.
Rs16918212 (OR = 0.72, p = 5.41 × 10−5 in identification;
OR = 0.83, p = 0.033 in replication), located on A2MP1,
was significantly associated with cough in the replication
cohorts with the same direction of effect as in the iden-
tification cohort (Table 2). The replication analyses on
dyspnea and phlegm showed no significant replication
(Table 3 and Table 4).
In addition, we performed GWA analyses on chronic
cough and phlegm (both defined as cough or phlegm for
at least 3 months per year) and found no significant
replication in these analyses either (Additional file 1:
Tables S1 and S2).
Discussion
To the best of our knowledge, this is the first GWA
study assessing genetic variants associated with cough,
dyspnea, and phlegm. In the identification cohort, we
identified 17, 19 and 14 SNPs associated with cough,
dyspnea and phlegm respectively at a p < 10−4 signifi-
cance level. In the meta-analysis of two independent
replication cohorts, one association was observed between
cough and rs16918212 located on chromosome 12 in in-
tron of A2MP1, and no associations with dyspnea and
phlegm were replicated.
The odds ratio for this SNP indicates that carriers of
the A allele have a lower risk to cough than subjects
with the wild type genotype. This SNP is located in an
intron of A2MP1 (alpha-2-macroglobulin pseudogene
1). A2MP1 has been associated with Alzheimer’s dis-
ease [25]. Pseudogenes are genomic DNA sequences
similar to normal genes but non-functional; they have
lost their gene expression in the cell or their ability to
code protein [26]. Some pseudogenes can be functional
when they are transcribed. Increasing evidence suggests
that pseudogenes may have important physiological
functions [26].
A major strength of this study the fact this is the first
GWA study trying to identify genetic susceptibility loci
for cough, dyspnea and phlegm, which included 2 verifica-
tion samples: one using the same methodology (Life-
Lines II) and one using similar methodology (Vlagtwedde-
Vlaardingen) as the discovery sample (LifeLines I). The
respiratory symptoms that we studied were defined based
on the standardized questionnaire of the ECRHS.
Table 2 Top SNPs (n = 17) associated with cough in the GWA study (all P < 1.0 × 10−4)




OR P OR P OR P OR P
rs11813494 10 638 kb 3′ of SFTA1P G 0.24 1.279 1.12E-06 1.110 0.114 0.776 0.096 1.049 0.427
rs840952 2 60 kb 5′ of SPRED2 G 0.10 1.212 1.09E-05 1.168 0.006 0.814 0.169 1.035 0.401
rs7633390 3 27 kb 5′ of ZNF717 T 0.18 1.237 2.24E-05 1.037 0.581 0.865 0.305 1.005 0.938
rs4977230 9 SLC24A2 T 0.71 0.817 3.35E-05 1.020 0.744 0.986 0.910 1.013 0.806
rs4780334 16 CIITA G 0.69 1.209 3.78E-05 0.985 0.802 0.875 0.295 0.964 0.500
rs844033 15 126 kb 5′ of NDN C 0.91 0.702 3.84E-05 1.163 0.115 1.213 0.342 1.172 0.068
rs422564 5 3.9 kb 3′ of TBCA T 0.21 1.201 3.97E-05 1.035 0.549 1.196 0.123 1.065 0.222
rs12153520 5 77 kb 3′ of HINT1 A 0.16 1.259 4.48E-05 1.012 0.875 1.020 0.904 1.013 0.844
rs893966 1 EPHB2 T 0.50 1.248 4.72E-05 0.992 0.909 0.909 0.532 0.975 0.707
rs6775462 3 ROBO2 C 0.50 0.739 4.81E-05 0.952 0.588 1.124 0.497 0.987 0.869
rs4766584 12 ACACB G 0.45 0.821 5.15E-05 0.929 0.234 0.994 0.964 0.941 0.274
rs16918212 12 A2MP1 A 0.20 0.717 5.41E-05 0.882 0.196 0.613 0.021 0.828 0.033
rs2623166 8 GEM T 0.13 1.293 7.68E-05 0.994 0.948 0.635 0.029 0.928 0.360
rs17729233 18 DSG4 G 0.44 1.257 7.89E-05 1.034 0.668 0.997 0.982 1.026 0.714
rs2850106 21 HLCS G 0.12 0.839 8.29E-05 1.050 0.384 0.998 0.989 1.040 0.434
rs10758982 9 PTPRD G 0.34 1.211 8.36E-05 0.967 0.602 0.827 0.163 0.939 0.284
rs2845804 21 HLCS C 0.18 0.841 9.93E-05 0.976 0.663 1.090 0.461 0.996 0.941
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Table 3 Top SNPs (n = 19) associated with dyspnea in the GWA study (all P < 1.0 × 10−4)




OR P OR P OR P OR P
rs10754237 1 LHX9 T 0.03 1.883 1.80E-06 0.921 0.642 1.523 0.057 1.120 0.412
rs658121 18 LAMA1 T 0.14 1.349 2.70E-06 1.039 0.638 0.776 0.070 0.965 0.614
rs6428425 1 8.1 kb 3′ of LHX9 G 0.97 1.864 2.90E-06 0.912 0.602 1.528 0.056 1.067 0.395
rs13388308 2 ATF2 T 0.19 0.751 4.59E-06 0.997 0.961 0.939 0.581 0.980 0.739
rs7236872 18 208 kb 3′ of CBLN2 A 0.53 1.237 7.79E-06 1.033 0.583 0.956 0.626 1.010 0.834
rs2243335 21 324 kb 5′ of MIR802 C 0.30 0.790 9.91E-06 1.014 0.821 1.077 0.438 1.032 0.540
rs4599120 2 4.3 kb 3′ of LOC84931 A 0.08 1.390 2.11E-05 0.942 0.551 0.895 0.466 0.927 0.368
rs12698902 7 AUTS2 G 0.27 1.239 3.73E-05 1.052 0.425 1.141 0.192 1.077 0.170
rs6977656 7 AUTS2 T 0.19 1.267 4.05E-05 1.065 0.375 1.109 0.358 1.077 0.214
rs2898237 21 329 kb 5′ of MIR802 G 0.30 0.805 4.21E-05 1.025 0.689 1.120 0.228 1.053 0.318
rs10231884 7 LOC100505881 A 0.58 0.817 4.61E-05 0.998 0.972 0.961 0.666 0.987 0.793
rs13232100 7 AUTS2 G 0.40 1.217 4.92E-05 1.036 0.544 1.130 0.197 1.062 0.233
rs11154774 6 22 kb 3′ of LOC154092 G 0.40 1.215 5.25E-05 1.083 0.173 1.083 0.173 1.081 0.113
rs7642234 3 DNAH12 A 0.26 1.253 6.30E-05 0.943 0.402 1.047 0.675 0.972 0.653
rs836692 2 30 kb 5′ of B3GALT1 T 0.32 1.225 6.44E-05 1.048 0.453 1.074 0.456 1.056 0.303
rs6852190 4 LIMCH1 T 0.36 0.813 6.88E-05 1.202 0.002 0.981 0.845 1.135 0.014
rs2063621 3 CADPS G 0.78 0.797 6.94E-05 1.108 0.125 1.142 0.212 1.118 0.049
rs10180670 2 225 kb 5′ of SOX11 A 0.17 0.775 7.00E-05 0.987 0.859 0.956 0.682 0.978 0.708
rs1391412 16 294 kb 3′ of TERF2IP A 0.44 0.826 8.37E-05 1.047 0.429 1.010 0.915 1.036 0.473
Table 4 Top SNPs (n = 14) associated with phlegm in the GWA study (all P < 1.0 × 10−4)




OR P OR P OR P OR P
rs4818199 21 79 kb 3′ of NCRNA00323 T 0.40 0.781 3.28E-06 0.936 0.314 1.048 0.711 0.959 0.470
rs13285576 9 488 kb 3′ of CYLC2 A 0.16 0.724 1.68E-05 1.022 0.800 0.847 0.324 0.986 0.827
rs6828886 4 171 kb 3′ of PAPSS1 C 0.42 0.794 1.81E-05 0.982 0.780 1.035 0.789 0.993 0.904
rs6040994 20 30 kb 3′ of BTBD3 T 0.15 1.371 1.93E-05 0.930 0.481 1.055 0.794 0.954 0.607
rs9643995 8 SGCZ T 0.03 0.471 2.79E-05 1.402 0.028 0.987 0.971 1.331 0.049
rs9831020 3 107 kb 3′ of LOC100507098 G 0.13 0.691 4.44E-05 1.014 0.892 0.988 0.948 1.008 0.933
rs7680755 4 230 kb 3′ of PAPSS1 T 0.41 0.801 4.66E-05 0.982 0.789 1.030 0.815 0.992 0.896
rs17534243 1 24 kb 3′ of LOC339442 G 0.21 1.265 4.91E-05 0.954 0.546 0.911 0.538 0.945 0.412
rs1156855 15 PAQR5 A 0.39 0.809 5.25E-05 1.026 0.700 1.221 0.126 1.063 0.300
rs6075458 20 145 kb 5′ of SLC24A3 A 0.20 0.759 5.79E-05 1.035 0.676 1.051 0.742 1.039 0.598
rs17792478 6 SENP6 G 0.33 1.233 5.92E-05 1.086 0.219 0.896 0.390 1.042 0.488
rs8025182 15 PAQR5 T 0.39 0.812 6.79E-05 1.016 0.812 1.269 0.063 1.064 0.289
rs6786757 3 SLC9A9 G 0.09 1.411 8.57E-05 1.136 0.290 1.092 0.714 1.127 0.266
rs7633390 3 27 kb 5′ of ZNF717 T 0.20 1.255 9.25E-05 0.970 0.691 0.994 0.967 0.975 0.710
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A GWA study has the advantage of being hypothesis-
free. This means that it has the potential of finding new
genes underlying disease phenotypes [27]. However, GWA
studies also have some disadvantages such as the need of
a large study sample, the need for replication, the inability
to address causation, and the inability to investigate rare
genetic variants [27].
A limitation of our study might be the fact that we
used a liberal p-value threshold (p < 10−4) for identifica-
tion of SNPs in the identification cohort to keep the risk
of not detecting a true association between genetic
markers and respiratory symptoms low. However, when
we assessed these associations in the replication cohorts,
the total number of significant associations in the repli-
cation meta-analysis is less than expected by chance (i.e.
1 out of the 50 SNPs analyzed for replication (i.e. 2%)
had a p-value < 0.05 and the same direction of effect as
in the identification analysis). In addition, given that
rs16918212 and the A2MP1 gene have not been associ-
ated with lung function impairment or respiratory dis-
eases we think the association is likely not a true finding.
We therefore conclude that there was no convincing
association between genetic markers and respiratory
symptoms in this study.
The lack of finding a plausible significant association
between SNPs and respiratory symptoms can possibly
be explained by the fact that a respiratory symptom can
be caused by different environmental exposures or can
be a presentation of different underlying diseases with
specific genetic or environmental origins. For example,
cough, can be triggered by smoking, air pollution and
occupational exposures. Susceptibility to these various
exposures may be genetically determined and susceptibil-
ity loci may differ between exposures. In addition, cough
is a common symptom of several chronic respiratory con-
ditions such as asthma, chronic obstructive pulmonary
disease (COPD), and lung cancer [28], but cough is also
present in non-respiratory conditions such as heart failure
[29]. Dyspnea is a common symptom not only in patients
with lung and heart diseases, but it is also fairly prevalent
among elderly individuals without apparent pre-existing
disease [5].
Conclusion
We did not find a convincing association between genetic
markers and the presence of respiratory symptoms cough,
dyspnea and phlegm. This lack of association between
genetic variants and respiratory symptoms may possibly
be due to the fact that we did not take the effect of envir-
onmental exposures that give rise to respiratory symptoms
into account. Therefore, the next logical step will be per-
forming a genome-wide interaction (GWI) study to iden-
tify genetic loci for respiratory symptoms in interaction
with known harmful environmental exposures.
Additional file
Additional file 1: Manhattan plots and additional analyses on chronic
cough and phlegm. (DOCX 584 kb)
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